Symbols

INKT

MiNK Therapeutics·NASDAQ

--(--)

INKT fundamentals

INKT Q4 2025 Earnings Preview

MiNK Therapeutics (INKT) expects to report earnings on Mar 31, 2026, with estimated revenue of 0 (YoY --), and EPS at -0.68 (YoY -9.68%).

Revenue estimate / YoY

EPS estimate / YoY

-0.68

-9.68%

Report date

Mar 31, 2026

INKT Earnings Call Summary for Q4,2025

Clinical Milestones: ARDS Phase II/III trial launching Q2 2026, with initial data expected H2 2026. GvHD trial dosing begins Q2 2026.
Financial Strength: $13.4M cash, 40% opex reduction, $3M post-year-end funding. Non-dilutive capital secures 70%+ pipeline programs.
Innovation: Off-the-shelf iNKT cells show durable survival in cancer (23+ months), 70% ARDS survival vs. 10% control. IL-15 combination trials under discussion.
Expansion Strategy: C-Further pediatric oncology collaboration, NIH GvHD funding, and Ukraine ARDS partnership enable rapid global execution.

Earnings

EPS

Revenue

Revenue & Expenses

Key Indicators

MiNK Therapeutics (INKT) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

MiNK Therapeutics (INKT)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

MiNK Therapeutics (INKT)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

MiNK Therapeutics (INKT)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown